AstraZeneca

An arrow incrementally going up stairs before pointing straight up Blue background

Biotech

AstraZeneca's $1.3B bet yields 2nd phase 3 blood pressure win

The phase 3 win for baxdrostat boost AstraZeneca's attempts to turn the molecule’s long half-life into a competitive advantage.

Nick Paul Taylor Oct 7, 2025 4:01am

AstraZeneca, Algen Biotechnologies pen $555M AI pact

Oct 6, 2025 8:00am

A close-up view of a jigsaw puzzle with a missing piece

Novo Holdings-backed biotech raises $205M to fill gout care gap

Sep 30, 2025 8:00am

Big Ben and Houses of Parliament On River Thames in London

Pharma execs grilled by UK lawmakers over R&D pullback

Sep 16, 2025 12:27pm

departures sign at airport

AZ pauses $271M UK expansion as British backtrack continues

Sep 12, 2025 2:44pm

United Kingdom UK UK

ABPI releases life sci competition report as UK investment lags

Sep 10, 2025 5:30pm